Cellebrite DI Ltd. (NASDAQ:CLBT) receives an average recommendation of “Buy” from brokers

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) have been given an average rating of “Buy” by the six analysts that currently cover the company, Marketbeat reports. Six research analysts have rated the stock with a “Buy” rating. The average 1-year price target among brokers that have covered the stock in the last year is $14.00.

A number of research analysts have recently commented on CLBT stock. Needham & Company LLC increased their price objective on shares of Cellebrite DI from $13.50 to $14.00 and gave the company a “buy” rating in a research report on Friday, May 24th. Lake Street Capital initiated coverage on shares of Cellebrite DI in a research report on Friday, April 19th. They set a “buy” rating and a $13.00 price target for the company. Finally, JPMorgan Chase & Co. increased their price objective on shares of Cellebrite DI from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Friday, May 24th.

Read our latest report on Cellebrite DI

Cellebrite DI Price-performance

NASDAQ CLBT opened at $13.55 on Friday. Cellebrite DI has a 12-month low of $6.36 and a 12-month high of $14.11. The company has a 50-day moving average of $12.20 and a 200-day moving average of $11.33. The company has a market cap of $2.79 billion, a price/earnings ratio of -23.36, a price/earnings/growth ratio of 1.69, and a beta of 1.50.

Cellebrite DI (NASDAQ:CLBT – Get Free Report) last released its quarterly earnings results on Thursday, May 23. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. Cellebrite DI had a negative net margin of 32.57% and a positive return on equity of 417.94%. The company had revenue of $89.60 million during the quarter, compared to the consensus estimate of $85.34 million. During the year-ago quarter, the company reported $0.03 EPS. The company’s quarterly revenue increased 25.8% compared to the same quarter last year. As a group, equities research analysts expect Cellebrite DI to report 0.34 EPS for the current year.

Hedge Funds Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently bought and sold shares of the company. Parallel Advisors LLC increased its shares in Cellebrite DI by 75.0% in the 4th quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock worth $30,000 after acquiring an additional 1,500 shares during the period. Quarry LP purchased a new position in Cellebrite DI in the 4th quarter worth approximately $36,000. nVerses Capital LLC purchased a new position in Cellebrite DI in the 2nd quarter worth approximately $103,000. TD Asset Management Inc purchased a new position in Cellebrite DI in the 2nd quarter worth approximately $121,000. Finally, Central Asset Investments & Management Holdings HK Ltd purchased a new position in Cellebrite DI in the 4th quarter worth approximately $113,000. Hedge funds and other institutional investors own 45.88% of the company’s shares.

Company Profile Cellebrite DI

(Get Free Report

Cellebrite DI Ltd. develops solutions for regulatory investigations in Europe, the Middle East, Africa, the Americas and Asia Pacific. The company’s DI solutions enable users to collect, review, analyze and manage digital data throughout the investigation cycle for regulatory investigations used in a variety of cases including child exploitation, homicide, counter-terrorism, border control, sexual crimes, human trafficking, corporate security, cryptocurrency and intellectual property theft.

Featured Stories

Get daily news and reviews for Cellebrite DI – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Cellebrite DI and related companies with MarketBeat.com’s FREE daily email newsletter.